Sonnet BioTherapeutics I... (SONN)
1.51
-0.07 (-4.43%)
At close: Jan 14, 2025, 3:59 PM
1.52
0.66%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.52 |
| Market Cap | 4.54M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -11.35 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.59 |
| Volume | 107,375 |
| Avg. Volume (20D) | 1,427,395 |
| Open | 1.60 |
| Previous Close | 1.58 |
| Day's Range | 1.50 - 1.60 |
| 52-Week Range | 1.41 - 18.72 |
| Beta | undefined |
About SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2006
Employees 12
Stock Exchange NASDAQ
Ticker Symbol SONN
Website https://www.sonnetbio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for SONN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 2416.56% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
-5.71%
Sonnet BioTherapeutics shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago ·
Source
-17.3%
Sonnet BioTherapeutics shares are trading lower. The company filed to sell common stock, terms not disclosed.
